Zobrazeno 1 - 10
of 1 471
pro vyhledávání: '"Jeffrey S Ross"'
Autor:
David P Carbone, David Spigel, Jeffrey S Ross, Karthikeyan Murugesan, Gerald Li, Richard S P Huang, Ryon P Graf, Geoffrey R Oxnard, Alexa Schrock, Liangliang Zhang, Khaled Tolba, Jacob Sands
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 1 (2023)
Background For patients with advanced non-small cell lung carcinoma (NSCLC), immune checkpoint inhibitor (ICPI) and chemotherapy (chemo) ICPI represent two distinct first-line standard-of-care regimens without clear and established biomarkers to info
Externí odkaz:
https://doaj.org/article/93d396e4896a4daf9ffa2a8edbac359e
Autor:
Jeffrey S Ross, Richard S P Huang, Jake G Maule, Lani K Clinton, Ryon P Graf, Jinpeng Xiao, Geoffrey R Oxnard
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 10 (2022)
Background Multiple PD-L1 immunohistochemistry (IHC) assays, including DAKO 22C3, DAKO 28-8, and Ventana SP142 PD-L1 IHC assays, have been approved by the Food and Drug Administration as a companion diagnostic (CDx) for various antiprogrammed death-1
Externí odkaz:
https://doaj.org/article/ff1128964776465ea8e84fbd8f9bd504
Autor:
Jeffrey S Ross, Karthikeyan Murugesan, Meagan Montesion, James Creeden, Lee A Albacker, Andrew D Kelly, Zheng Kuang, Richard S P Huang, Douglas I Lin, Umut Demirci
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 11 (2021)
Externí odkaz:
https://doaj.org/article/824504b566ee404e875ec16f65f96845
Autor:
Lajos Pusztai, Richard Huang, Shakti Ramkissoon, Jeffrey S Ross, Konstantinos Syrigos, Myrto K Moutafi, Weiwei Tao, James Haberberger, Ioannis A Vathiotis
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 4 (2021)
Assessment of programmed cell death-ligand 1 (PD-L1) expression by immunohistochemistry (IHC) is the definite diagnostic test to guide treatment for patients with advanced-stage non-small cell lung cancer. Intratumoral heterogeneity and discrepancy o
Externí odkaz:
https://doaj.org/article/1962fa861872475fb84fad62ac0a3cc1
Autor:
Brian Alexander, Lajos Pusztai, David L Rimm, Priti Hegde, Mariya Rozenblit, Richard Huang, Natalie Danziger, Shakti Ramkissoon, Kim Blenman, Jeffrey S Ross
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
Programmed Death Ligand 1 (PD-L1) positivity rates differ between different metastatic sites and the primary tumor. Understanding PD-L1 expression characteristics could guide biopsy procedures and motivate research to better understand site-specific
Externí odkaz:
https://doaj.org/article/8919ed55a8984c7d8d3fdbc871c78cce
Autor:
Jeffrey S Ross, Skye A Buckner Petty, Waleed Brinjikji, Joseph M Hoxworth, Vance T Lehman, Erik H Middlebrooks, Ameet C Patel, Christopher P Wood
Publikováno v:
PLoS ONE, Vol 15, Iss 9, p e0237856 (2020)
Background and purposeMR contrast-enhanced techniques are undergoing increased scrutiny since the FDA applied a warning for gadolinium-based MR contrast agents due to gadolinium deposition within multiple organ systems. While CE-MRA provides excellen
Externí odkaz:
https://doaj.org/article/f3217057bd9b42a790bb6c3fc1aa631e
Publikováno v:
Indian Journal of Pathology and Microbiology, Vol 61, Iss 1, Pp 27-30 (2018)
Background: Myeloid cell leukemia-1 (Mcl-1) is a member of the B-cell lymphoma 2 family known to play a significant role in the regulation of apoptosis. Mcl-1 expression has been studied in nonsmall cell lung cancer (NSCLC) cell lines but has not bee
Externí odkaz:
https://doaj.org/article/575569e86fbc4cb290472d0f494a7807
Autor:
James X Sun, Yuting He, Eric Sanford, Meagan Montesion, Garrett M Frampton, Stéphane Vignot, Jean-Charles Soria, Jeffrey S Ross, Vincent A Miller, Phil J Stephens, Doron Lipson, Roman Yelensky
Publikováno v:
PLoS Computational Biology, Vol 14, Iss 2, p e1005965 (2018)
A key constraint in genomic testing in oncology is that matched normal specimens are not commonly obtained in clinical practice. Thus, while well-characterized genomic alterations do not require normal tissue for interpretation, a significant number
Externí odkaz:
https://doaj.org/article/2c3540ac65e64877b4ea2ae6249ea3de
Autor:
Caren Stuebe, Breck A. Jones, Arjun Syal, Rudy J. Rahme, Evelyn L. Turcotte, L. Gerard Toussaint, Jeffrey S. Ross, Bernard R. Bendok
Publikováno v:
World Neurosurgery. 176:74-80
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dbec4fe1af792c93ee2016e9f2c63b97
https://doi.org/10.1016/j.wneu.2023.03.056
https://doi.org/10.1016/j.wneu.2023.03.056
Autor:
Natalie Danziger, Ethan S Sokol, Ryon P Graf, Matthew C Hiemenz, Jake Maule, Vamsi Parimi, Carlo Palmieri, Lajos Pusztai, Jeffrey S Ross, Richard S P Huang
Publikováno v:
The Oncologist. 28:319-326
Background In 2020, pembrolizumab was approved as a therapy for triple-negative breast cancer (TNBC) with the companion diagnostic DAKO 22C3 programmed death ligand-1 (PD-L1) immunohistochemistry assay. The study aimed to determine the landscape of P
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::933a9d43ae67b7b16da64a54684bde79
https://doi.org/10.1093/oncolo/oyad025
https://doi.org/10.1093/oncolo/oyad025